Merck & Co., Inc. beat EPS estimates 79% of the time across 19 reported quarters (15 beats, 4 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q32026 FY2026 | — | — | — | Miss |
| Q22026 FY2026 | $-0.26 | $-0.13 | +50.0% | Beat |
| Q12026 FY2026 | $-1.51 | $-1.28 | +15.2% | Beat |
| Q42025 FY2025 | $2.03 | $2.04 | +0.5% | Beat |
| Q42024 FY2024 | $1.85 | $1.72 | -7.0% | Miss |
| Q42023 FY2023 | $-0.09 | $0.03 | +133.3% | Beat |
| Q3 FY2023 | $1.95 | $2.13 | +9.2% | Beat |
| Q2 FY2023 | $-2.17 | $-2.06 | +5.1% | Beat |
| Q1 FY2023 | $1.32 | $1.40 | +6.1% | Beat |
| Q42022 FY2022 | $1.56 | $1.62 | +3.9% | Beat |
| Q32022 FY2022 | $1.67 | $1.85 | +10.8% | Beat |
| Q22022 FY2022 | $1.70 | $1.87 | +10.0% | Beat |
Back to MRK overview · MRK holders · MRK KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.